Indegene Limited · NSE:INDGN
Indegene — Merger or Acquisition (October 2025)
13 slides from Indegene's merger presentation, Oct 2, 2025
Slide 1: Exchange intimation letter: Investor Presentation
INDGN/SE/2025-26/62 October 02, 2025 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Mada
Slide 2: Indegene Enters into a Definitive Agreement to Acquire BioPharm
Indegene Enters into a Definitive Agreement to Acquire BioPharm 1
Slide 3: Disclaimer
Disclaimer Certain statements made in this presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference betwe
Slide 4: Indegene Announces Acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma
Indegene Announces Acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma 1st October 2025 © 2025 Indegene. All rights reserved. 3
Slide 5: Indegene And Biopharm Come Together To Solidify Its Position As Category Leader
Indegene And Biopharm Come Together To Solidify Its Position As Category Leader In Data-driven Omnichannel & AdTech Space More Data | More Engagement | More Brand Impact © 2025 Indegene. All rights reserved. 4
Slide 6: BioPharm Overview
BioPharm Overview FOUNDED LOCATION GROSS REVENUE 2024 NET REVENUE 2024 2005 Pennsylvania, USA $38.1Mn $29.2Mn BUSINESS OFFERINGS CUSTOMER PROFILE EMPLOYEES TEAM Provider of hyper-targeted Serves 17 of the top 25 ~100 Team Members in Highly skilled executive HCP engagement global pharma companies US
Slide 7: BioPharm – Business Model
BioPharm – Business Model Integrated, closed-loop precision marketing engine that uniquely combines media strategy, campaign execution, and thought-leader driven content- from zero-waste marketing to launch acceleration BioPharm - Capabilities Developed a data engine to drive ROI and precisely targe
Slide 8: BioPharm Builds Market Strength Through Its Two Core Offerings
BioPharm Builds Market Strength Through Its Two Core Offerings A full-service, data-driven agency designed to address clients' evolving needs across the commercial lifecycle Creates a push engagement through Creates a pull engagement through Outcomes programmatic campaigns precision and zero waste m
Slide 9: Strategic Rationale
Strategic Rationale BioPharm and Indegene emerge as a powerful player in the Omnichannel and Brand Activation space, combining the right mix of credentials, capabilities, talent, and client access becoming a true force in the market Deeper penetration across channels and marketing mix (Email, Progra
Slide 10: Empowering Indegene's Brand Offerings With The Power Of Data
Empowering Indegene’s Brand Offerings With The Power Of Data Stronger Unified Platform + Enriched data set (1.8Mn to 3Mn HCP records) powering Expanding into emerging media channels while better insights and precision marketing strengthening performance across existing ones, backed by proven brand e
Slide 11: Indegene + BioPharm: Leader in Data-Driven Omnichannel and Media
Indegene + BioPharm: Leader in Data-Driven Omnichannel and Media + Revenue $335.7 Mn $38.1 Mn $373.8 Mn EBITDA $66.5 Mn + $7.9 Mn $74.4 Mn Brand Activation segment $43.0 Mn $38.1 Mn $81.1 Mn Strengths Enterprise customer Omnichannel Marketing Enterprise flavoured relationships, Technology (Superchar
Slide 12: Transaction Details
Transaction Details Transaction Structure: 100% ownership of BioPharm Parent Holding, Inc. along with its subsidiaries (BioPharm Communications LLC and Addressable Health LLC), collectively “BioPharm” Purchase Price: $104 Mn plus adjustment for any excess / deficit cash and working capital at closin
Slide 13: Thank you
Thank you in\degene’